Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease

• DOI: 10.1080/07853890.2024.2446692
• Publication Date: 2024-12-28T10:25:02Z
• Authors: Can Chen; Yang Fan; Ying Xu; Yaping Xie; Kuang Chen; Xilian Huang; Daquan Gao; Junfeng Tan; Lirong Liu; Shenxian Qian; Pengfei Shi
• Keywords: Regimen; Myeloid leukaemia

Background The management of high-risk acute myeloid leukaemia (AML) remains challenging, highlighting the need for innovative conditioning strategies beyond current regimens.